Rebecca A. Brophy Partner

Rebecca focuses her practice on corporate transactions, including mergers and acquisitions, financings, asset purchases and dispositions and strategic collaborations. She has represented public and private growth companies across diverse industry sectors as well as private equity and venture capital firms.

Rebecca regularly advises her clients on general corporate needs, strategic planning, corporate and board governance, and compliance matters.

Experience

Representation of a semiconductor and global solid state LED lighting manufacturing company in an agreement to purchase the assets of the radio frequency (RF) power business of a publicly traded semiconductor company for €345 million in cash.

Representation of a global solid state LED lighting semiconductor manufacturing company in connection with its announced agreement for its $850 million sale of assets to a publicly traded German semiconductor company. The transaction was terminated before completion due to regulatory considerations.

Representation of a private materials and recycling technology company in an agreement to acquire assets from a leading supplier of high performance catalysts for $27 million in cash plus potential additional amounts via an earn out.

Representation affiliated multidisciplinary engineering, investigation and construction companies in a sale of assets process involving multiple potential buyers, culminating in the sale of substantially all of their assets to a wireless network services company.

Representation of a global financial services technology company in its acquisition of a leading provider of deal analytics and valuation technology.

Representation of a SaaS company in its sale to a data integration public company.

Representation of a leading CRO in Asia in the acquisition of CRO assets in the United States.

Representation of a major regional distributor of industrial gases in a strategic merger of equals of two similarly situated businesses.

Representation of a public contract research organization in multiple acquisitions of private company strategic targets totaling approximately $500 million.

Representation of a public telecommunications company in multiple acquisitions of private company strategic targets totaling approximately $750 million, including acquisitions in the United States, Colombia and Mexico.

Representation of a public defense contractor in multiple acquisitions of private and public company strategic targets totaling approximately $500 million.

Representation of a public information technology company in its sale valued at approximately $340 million.

Representation of a private equity fund in its acquisition of a public health services company valued at approximately $250 million.

Representation of venture capital funds in multiple financings of private companies, including companies in the biotechnology and fashion industries, totaling approximately $400 million.

Representation of a privately held leading manufacturer of beverage and foodservice equipment in its sale to a public company for $108 million in cash.

Representation of a publicly traded health services company in the acquisition of a health services division of a privately held company for $105 million in cash.

Representation of a private biotechnology company in financings totaling approximately $50 million.

Representation of multiple public and private companies in general corporate and governance matters including commercial agreements, board and committee advice and general corporate advice.

Representation of a leading provider of pharmacy-based patient care solutions and medication synchronization services to independent and chain pharmacies in its approximately $41 million sale of the company to a publicly traded buyer.

Representation of a global solid state LED lighting and semiconductor manufacturing company in a Hong Kong joint venture to sell mid-power lighting class LED packaged products.

Representation of a publicly traded health information technologies and clinical research company in its acquisition of a consulting business focusing on orphan drug designations.

Representation of a publicly traded health information technologies and clinical research company in its sale of a consulting line of business.

Representation of a private equity fund in its acquisition of a specialty pharmaceutical company.

  • University of San Diego School of Law, JD, magna cum laude, Order of the Coif, 2006
  • The Catholic University of America, BA, magna cum laude, Phi Beta Kappa, 2001

Member, ACG Raleigh Durham Board of Directors, 2017-2018

Graduate of the Greater Raleigh Chamber of Commerce 29th Class Leadership Raleigh Program, 2014

Grants Committee of the Board of Directors, Susan G. Komen for the Cure, San Diego, California, 2010-2012

  • North Carolina

North Carolina Super Lawyers, Rising Star, 2014-2018

Back to top